(Reuters) - The agency's Committee for Medicinal Products for Human Use
also backed the Swiss group's Exelon Patch, which delivers a treatment for Alzheimer's disease through a skin patch, and once-yearly Aclasta for women with postmenopausal oesteoporosis. Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use are normally endorsed by the European Commission within a couple of months.
Read more at Reuters.com Government Filings News
also backed the Swiss group's Exelon Patch, which delivers a treatment for Alzheimer's disease through a skin patch, and once-yearly Aclasta for women with postmenopausal oesteoporosis. Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use are normally endorsed by the European Commission within a couple of months.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment